Business Context and Reporting Period
This Form 8-K, dated May 20, 2022, is filed by Data Knights Acquisition Corp. (DKDC), a Delaware corporation and emerging growth company. The filing discloses a definitive Agreement and Plan of Merger entered into on April 25, 2022, with OneMedNet Corporation, Inc. (OneMedNet). Under the agreement, a merger subsidiary will merge with OneMedNet, making OneMedNet a wholly-owned subsidiary of Data Knights. The filing includes an investor presentation (Exhibit 99.1) but explicitly states it is not a proxy statement or an offer to sell securities.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Data Knights Acquisition Corp. or OneMedNet. The document serves as a disclosure of the merger agreement and references an investor presentation for further details, but the presentation's specific numerical data is not included in the text provided.
Material Changes
The primary material change is the execution of the Merger Agreement on April 25, 2022, initiating the business combination process. No comparative financial performance data or changes in operating metrics versus prior periods are disclosed in this specific filing.
Guidance, Outlook, and Risks
Outlook and Forward-Looking Statements: The filing contains forward-looking statements regarding the likelihood of consummating the transaction, implied enterprise value, and future ownership structure. Management notes that actual results may differ materially from projections due to various uncertainties.
Risks and Contingencies: The filing outlines significant risks that could prevent the transaction from closing or impact future performance, including:
- Failure to complete the transaction by the business combination deadline or obtain an extension.
- Failure to satisfy conditions, including stockholder approval and minimum cash requirements following redemptions.
- Lack of a third-party valuation for the transaction.
- Disruption to OneMedNet's business relationships and operations.
- Regulatory and legal challenges, including potential litigation.
- Volatility in the price of Data Knights' securities.
- Risks related to OneMedNet's ability to develop and commercialize products, achieve profitability, or raise additional capital.
Management Commentary: The company advises stockholders to await the definitive Prospectus and Proxy Statement for complete information regarding the business combination and voting matters.
Investor Verification Checklist
- Verify the definitive terms of the Merger Agreement, including the exchange ratio and implied valuation, in the upcoming Prospectus and Proxy Statement.
- Confirm the minimum cash amount required to close the transaction and the potential impact of stockholder redemptions.
- Review OneMedNet's audited financial statements and pro forma financial information once filed.
- Monitor the status of regulatory approvals and the timeline for the stockholder vote.
- Assess the risks associated with OneMedNet's product development pipeline and commercialization strategy.